“We’re fortunate to have Susan and Alex, two of the strongest leaders in the genomics industry, take on these large, important roles.” - Francis deSouza, Chief Executive Officer of Illumina. We are happy to share Susan Tousi will become Illumina’s Chief Commercial Officer, and Alex Aravanis, MD, PhD, will become Chief Technology Officer, Head of Research and Product Development.
We are thrilled to be included in the inaugural TIME100 Most Influential Companies list! #TIME100Companies
We have been included in two prestigious lists that recognize organizations demonstrating leadership in diversity and inclusion: Bloomberg LP Gender Equality Index (GEI) and the Human Rights Campaign Corporate Equality Index (CEI). We are inspired that our diversity, inclusion and fairness initiative continues to build opportunities to strengthen the relationship between our employees, our company and our communities. #CEI2021 #BloombergGEI
We are honored to be included in this year’s #2021SPGlobalYearbook and designated as an Industry Mover. Congratulations to all our fellow #ESG #sustainability leaders!
2020 has presented many challenges. But, through it all, we’ve been determined to support our employees, customers, and communities. Because of this, we are honored to be recognized by Forbes and JUST Capital in the #AmericasMostJUST and #1 spot for workers in the Pharmaceuticals and Biotech Companies.
We are joining a $100 M USD partnership to support the Africa Centres for Disease Control and Prevention (Africa CDC) in launching the Africa Pathogen Genomics Initiative (APGI), which will expand access to NGS, boosting pathogen surveillance across Africa.
We invite you to attend Illumina’s Consumer & Healthcare Genomics Virtual Summit on October 14. We will be addressing the global theme of “meeting the unmet need in genetic counseling”. To find out more and register, click here:
Our commitment to diversity, inclusion, and fairness in all that we do is a core part of our culture at Illumina. We’re thrilled to welcome Dr. Lisa Toppin as our new VP of Diversity & Inclusion (D&I) to help us continue that commitment in new and meaningful ways.
At Illumina, we firmly believe that no one should be paid differently because of their gender, race, age, ethnicity, sexual orientation or national origin. We continue to commit to global pay equity, and we are proud to have confirmed a zero gap in pay. Global pay equity is just one part of Illumina’s ongoing commitment to diversity, inclusion and fairness in all we do across the company.
We are excited to announce our agreement to acquire GRAIL, Inc., the company detecting cancer early with a simple blood test. Beating cancer begins with finding it. Together we have the opportunity to revolutionize cancer testing & support our mission to improve human health.